

Anguraj Sadanandam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1669995/publications.pdf>

Version: 2024-02-01

67
papers

10,794
citations

159358

30
h-index

110170

64
g-index

78
all docs

78
docs citations

78
times ranked

18973
citing authors

#	ARTICLE	IF	CITATIONS
1	The consensus molecular subtypes of colorectal cancer. <i>Nature Medicine</i> , 2015, 21, 1350-1356.	15.2	3,596
2	Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. <i>Nature Medicine</i> , 2011, 17, 500-503.	15.2	1,460
3	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. <i>Science</i> , 2018, 359, 920-926.	6.0	1,199
4	A colorectal cancer classification system that associates cellular phenotype and responses to therapy. <i>Nature Medicine</i> , 2013, 19, 619-625.	15.2	831
5	Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer. <i>Cell</i> , 2014, 158, 185-197.	13.5	553
6	Subtype and pathway specific responses to anticancer compounds in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2724-2729.	3.3	417
7	Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. <i>Journal of Pathology</i> , 2019, 248, 51-65.	2.1	215
8	Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. <i>Cancer Cell</i> , 2019, 36, 35-50.e9.	7.7	179
9	Chemokines in tumor angiogenesis and metastasis. <i>Cancer and Metastasis Reviews</i> , 2007, 26, 453-467.	2.7	162
10	A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. <i>Cancer Discovery</i> , 2015, 5, 1296-1313.	7.7	145
11	ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2019, 25, 3392-3403.	3.2	144
12	Small-Molecule Antagonists for CXCR2 and CXCR1 Inhibit Human Melanoma Growth by Decreasing Tumor Cell Proliferation, Survival, and Angiogenesis. <i>Clinical Cancer Research</i> , 2009, 15, 2380-2386.	3.2	136
13	The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer. <i>Breast Cancer Research</i> , 2010, 12, R18.	2.2	115
14	CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. <i>British Journal of Cancer</i> , 2009, 100, 1638-1646.	2.9	110
15	Molecular subtypes in cancers of the gastrointestinal tract. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 333-342.	8.2	99
16	Cathepsin G Enhances Mammary Tumor-Induced Osteolysis by Generating Soluble Receptor Activator of Nuclear Factor- κ B Ligand. <i>Cancer Research</i> , 2008, 68, 5803-5811.	0.4	84
17	Semaphorin 5A promotes angiogenesis by increasing endothelial cell proliferation, migration, and decreasing apoptosis. <i>Microvascular Research</i> , 2010, 79, 1-9.	1.1	81
18	Context matters- consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. <i>Annals of Oncology</i> , 2019, 30, 520-527.	0.6	80

#	ARTICLE	IF	CITATIONS
19	A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 394.	0.7	72
20	Reconciliation of classification systems defining molecular subtypes of colorectal cancer. <i>Cell Cycle</i> , 2014, 13, 353-357.	1.3	69
21	Transforming growth factor β signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation. <i>Cancer Science</i> , 2009, 100, 71-81.	1.7	58
22	High gene expression of semaphorin 5A in pancreatic cancer is associated with tumor growth, invasion and metastasis. <i>International Journal of Cancer</i> , 2010, 127, 1373-1383.	2.3	58
23	Small interfering RNA-mediated CXCR1 or CXCR2 knockdown inhibits melanoma tumor growth and invasion. <i>International Journal of Cancer</i> , 2010, 126, 328-336.	2.3	54
24	Cannabinoids in the landscape of cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2507-2534.	1.2	53
25	Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation. <i>British Journal of Cancer</i> , 2012, 107, 501-507.	2.9	48
26	Refining colorectal cancer classification and clinical stratification through a single-cell atlas. <i>Genome Biology</i> , 2022, 23, 113.	3.8	48
27	Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses. <i>Npj Breast Cancer</i> , 2019, 5, 21.	2.3	43
28	Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes?. <i>Cancer Research</i> , 2016, 76, 5195-5200.	0.4	41
29	Identification of Functional Cell Adhesion Molecules with a Potential Role in Metastasis by a Combination of in vivo Phage Display and in silico Analysis. <i>OMICS A Journal of Integrative Biology</i> , 2007, 11, 41-57.	1.0	39
30	Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes. <i>Scientific Reports</i> , 2019, 9, 7665.	1.6	36
31	Prediction of epigenetically regulated genes in breast cancer cell lines. <i>BMC Bioinformatics</i> , 2010, 11, 305.	1.2	34
32	Microenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticity. <i>Nature Communications</i> , 2018, 9, 3917.	5.8	33
33	A Novel Statistical Method to Diagnose, Quantify and Correct Batch Effects in Genomic Studies. <i>Scientific Reports</i> , 2017, 7, 10849.	1.6	32
34	A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. <i>Annals of Oncology</i> , 2018, 29, 2356-2362.	0.6	32
35	A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. <i>BMC Medicine</i> , 2009, 7, 77.	2.3	31
36	GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. <i>Nature</i> , 2022, 607, 163-168.	13.7	31

#	ARTICLE	IF	CITATIONS
37	Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. <i>Oncogene</i> , 2019, 38, 1717-1733.	2.6	29
38	A blood transcriptome-based analysis of disease progression, immune regulation, and symptoms in coronavirus-infected patients. <i>Cell Death Discovery</i> , 2020, 6, 141.	2.0	28
39	DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. <i>Communications Biology</i> , 2021, 4, 155.	2.0	26
40	Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. <i>Gut</i> , 2021, 70, 1904-1913.	6.1	24
41	Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. <i>ESMO Open</i> , 2020, 5, e000847.	2.0	21
42	Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer. , 2021, 9, e001717.		19
43	The molecular biology of pancreatic neuroendocrine neoplasms: Challenges and translational opportunities. <i>Seminars in Cancer Biology</i> , 2020, 61, 132-138.	4.3	16
44	Enhanced expression and shedding of receptor activator of NF- κ B ligand during tumor-bone interaction potentiates mammary tumor-induced osteolysis. <i>Clinical and Experimental Metastasis</i> , 2009, 26, 797-808.	1.7	15
45	Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 693-703.	1.1	15
46	Identification and Characterization of Poorly Differentiated Invasive Carcinomas in a Mouse Model of Pancreatic Neuroendocrine Tumorigenesis. <i>PLoS ONE</i> , 2013, 8, e64472.	1.1	15
47	Characterization of chemoradiation-induced changes in immune cells and targets for personalized therapy in locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 589-589.	0.8	15
48	Identification of Semaphorin 5A Interacting Protein by Applying Apriori Knowledge and Peptide Complementarity Related to Protein Evolution and Structure. <i>Genomics, Proteomics and Bioinformatics</i> , 2008, 6, 163-174.	3.0	14
49	Semaphorin 5A mediated cellular navigation: Connecting nervous system and cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 485-493.	3.3	14
50	Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. <i>ESMO Open</i> , 2019, 4, e000489.	2.0	14
51	Immunological combination treatment holds the key to improving survival in pancreatic cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2897-2911.	1.2	14
52	A Cross-Species Analysis of a Mouse Model of Breast Cancer-Specific Osteolysis and Human Bone Metastases Using Gene Expression Profiling. <i>BMC Cancer</i> , 2011, 11, 304.	1.1	13
53	Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study. <i>ESMO Open</i> , 2021, 6, 100073.	2.0	12
54	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. <i>Nature Communications</i> , 2021, 12, 6738.	5.8	10

#	ARTICLE	IF	CITATIONS
55	Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. <i>JCO Precision Oncology</i> , 2020, 4, 1152-1162.	1.5	6
56	Consensus molecular subtypes and CRCassigener classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4016-4016.	0.8	6
57	Reply to Colorectal cancer classification based on gene expression is not associated with FOLFIRI response. <i>Nature Medicine</i> , 2014, 20, 1231-1232.	15.2	5
58	Is the tumour microenvironment a critical prognostic factor in early-stage colorectal cancer?. <i>Annals of Oncology</i> , 2019, 30, 1538-1540.	0.6	4
59	ARAF suppresses ERBB3 expression and metastasis in a subset of lung cancers. <i>Science Advances</i> , 2022, 8, eabk1538.	4.7	4
60	MCAM: A Database to Accelerate the Identification of Functional Cell Adhesion Molecules. <i>Cancer Informatics</i> , 2008, 6, CIN.S341.	0.9	3
61	The 2nd Conference and Workshop of The Cancer Genome Atlas (TCGA) in India: Towards Team Science for Multi-omics Cancer Research in South Asia. <i>Ecancermedicalscience</i> , 2021, 15, ed111.	0.6	2
62	A blood transcriptome-based analysis of disease progression, immune regulation, and symptoms in coronavirus-infected patients. <i>Cell Death Discovery</i> , 2020, 6, .	2.0	2
63	Molecular Classification of Colon Cancer: Perspectives for Personalized Adjuvant Therapy. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 296-302.	1.0	1
64	polyClustR: defining communities of reconciled cancer subtypes with biological and prognostic significance. <i>BMC Bioinformatics</i> , 2018, 19, 182.	1.2	1
65	A Machine-Learning Tool Concurrently Models Single Omics and Phenome Data for Functional Subtyping and Personalized Cancer Medicine. <i>Cancers</i> , 2020, 12, 2811.	1.7	0
66	Gene expression profiling using a unique murine mammary tumor model reveal role of novel genes regulating tumorâ€stromal interaction in mammary tumorâ€induced osteolysis. <i>FASEB Journal</i> , 2006, 20, A222.	0.2	0
67	Bioinformatics Analysis to Identify Cell Adhesion Molecules in Cancer. , 2010, , 309-325.		0